Search Results
Your search for all items matches 4339 pages
Showing 101 - 150
Cynthia X. Ma, MD, PhD, on Metastatic Breast Cancer: Early Results on Copanlisib, Fulvestrant, and Abemaciclib
Cynthia X. Ma, MD, PhD, of Washington University School of Medicine in St. Louis, discusses phase I findings showing the safety and tolerability of copanlisib and fulvestrant in combination with continuous or intermittent abemaciclib in patients with estrogen receptor–positive, HER2-negative...
5-Year Outcomes of the IDEA Trial: Omission of Radiotherapy After Breast-Conserving Surgery for Low-Risk Patients
As reported in the Journal of Clinical Oncology by Reshma Jagsi, MD, DPhil, and colleagues, a 5-year analysis of the IDEA trial showed a very low rate of recurrence with the omission of radiotherapy after breast-conserving surgery in patients at low clinical and genomic risk for disease ...
HER2CLIMB-02: Tucatinib Plus T-DM1 Extends Progression-Free Survival vs T-DM1 Alone in Advanced HER2-Positive Breast Cancer
Adding the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1) to the HER2-targeted agent tucatinib extended progression-free survival by about 2 months vs treatment with T-DM1 alone among patients with unresectable, locally advanced or metastatic HER2-positive breast cancer, according to...
Hope S. Rugo, MD, on Advanced Breast Cancer: Patient-Reported Outcomes From the CAPItello-291 Trial
Hope S. Rugo, MD, of the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses patient-reported outcomes from the phase III CAPItello-291 study; the trial centered on adding capivasertib to fulvestrant in patients with aromatase inhibitor–resistant,...
Eleftherios P. Mamounas, MD, on Locoregional Irradiation, Axillary Lymph Node Involvement, and Conversion to Negative Nodes
Eleftherios P. Mamounas, MD, of Orlando Health Cancer Institute, discusses primary outcomes from the NRG Oncology/NSABP B-51/RTOG 1304 study of locoregional irradiation in patients with biopsy-proven axillary node involvement at presentation who become pathologically node-negative after neoadjuvant ...
Daniel Kates-Harbeck, MD Candidate, and Nadia Harbeck, MD, PhD, on Personalizing Breast Cancer Management With AI: Novel Approach to Predicting Outcomes
Nadia Harbeck, MD, PhD, of LMU University Hospital and Ludwig Maximilian University of Munich, and Daniel Kates-Harbeck, of the West German Study Group and an MD Candidate at Ludwig Maximilian University of Munich, discuss a learning-based neural network developed by Mr. Kates-Harbeck to predict...
Luca Gianni, MD, on Locally Advanced, HER2-Positive Breast Cancer: New Data on Neoadjuvant Therapy and Atezolizumab
Luca Gianni, MD, of Milan’s Fondazione Michelangelo, discusses findings from the APTneo Michelangelo trial, which showed that adding atezolizumab to chemotherapy and trastuzumab plus pertuzumab did not significantly increase the rate of pathologic complete response (pCR) in women with HER2-positive ...
Oleg Gluz, MD, on Response to Endocrine Therapy: Findings From the ADAPTcycle Trial
Oleg Gluz, MD, of the West German Study Group and Breast Center Niederrhein, discusses the impact of age and ovarian function suppression in response to preoperative endocrine treatment for both pre- and postmenopausal patients with early-stage breast cancer. He describes ways in which the outcome...
Barbara Pistilli, MD, on HR+, HER2– Advanced Breast Cancer: Update on Capivasertib Plus a CDK4/6 Inhibitor and Fulvestrant
Barbara Pistilli, MD, of France’s Gustave Roussy, discusses a phase Ib analysis from the CAPItello-292 study, which showed capivasertib plus palbociclib plus fulvestrant was tolerable at all dose levels in heavily pretreated patients with hormone receptor–positive, HER2-negative advanced breast...
Sherene Loi, MD, PhD, on Biomarker Results in ER+, HER2– Primary Breast Cancer Following Neoadjuvant Chemotherapy With or Without Nivolumab
Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses an exploratory analysis of CheckMate 7FL which showed that patients with PD-L1–positive, high-risk, estrogen receptor–positive, HER2-negative primary breast cancer may achieve substantial pathologic complete response rates ...
Sherene Loi, MD, PhD, on Triple-Negative Breast Cancer: Phase II Study Results of Nivolumab, Carboplatin, and Paclitaxel
Sherene Loi, MD, PhD, of Australia’s Peter McCallum Cancer Centre, discusses recent data showing that for patients with stage I/II triple-negative breast cancer, 12 weeks of a neoadjuvant nonanthracycline chemotherapy regimen with nivolumab may be efficacious with either concurrent or lead-in...
Aditya Bardia, MD, MPH, on Early-Stage, High-Risk Breast Cancer: New Data on Pembrolizumab Plus Chemotherapy
Aditya Bardia, MD, MPH, of Massachusetts General Hospital Cancer Center, discusses phase III findings from the KEYNOTE-756 study, which showed that adding pembrolizumab to chemotherapy increases the pathologic complete response rate and lowers the residual cancer burden in patients with...
Daniel G. Stover, MD, on Early-Stage Breast Cancer: A Biomarker Analysis From the PALLAS Trial
Daniel G. Stover, MD, of The Ohio State University Comprehensive Cancer Center, discusses a biomarker analysis from the PALLAS adjuvant trial, which compared 2 years of the CDK4/6 inhibitor palbociclib with endocrine therapy vs endocrine therapy alone, as adjuvant treatment for patients with stage...
Senthil Damodaran, MD, PhD, on Locally Advanced or Metastatic Breast Cancer: Phase II Results on Futibatinib
Senthil Damodaran, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses final results from the FOENIX-MBC2 study of the efficacy and safety of futibatinib in patients with locally advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring high-level...
Nicholas C. Turner, MD, PhD, on High-Risk Early-Stage Breast Cancer: Profiling Primary Tumors
Nicholas C. Turner, MD, PhD, of The Royal Marsden Hospital NHS Foundation Trust, and the Institute of Cancer Research, London, discusses the monarchE trial, which evaluated molecular profiling of archived primary tumor tissue from patients with hormone receptor–positive, HER2-negative,...
Gabriel N. Hortobagyi, MD, on Early Breast Cancer: Final Invasive Disease–Free Analysis From the NATALEE Trial
Gabriel N. Hortobagyi, MD, of The University of Texas MD Anderson Cancer Center, discusses findings from the NATALEE trial, which continued to demonstrate improved invasive disease–free survival with ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) over a NSAI alone in patients with...
Combining Ribociclib With Hormone Therapy Improves Patient Outcomes in Early-Stage Breast Cancer: NATALEE
Targeted treatment with ribociclib plus hormone therapy provided significant invasive disease–free survival benefits in patients with early-stage hormone receptor–positive, HER2-negative breast cancer at risk of disease recurrence. Results from the phase III NATALEE trial, led by researchers at The ...
Abemaciclib Plus AI in Postmenopausal Patients With Advanced Breast Cancer: Final Overall Survival Analysis From MONARCH 3
Final overall survival results from the MONARCH 3 trial were reported in a late-breaking presentation during the 2023 San Antonio Breast Cancer Symposium (Abstract GS01-12). MONARCH 3 evaluated abemaciclib in combination with an aromatase inhibitor (AI) compared with an AI alone as initial...
Some Breast Cancer Survivors May Safely De-escalate Mammography 3 Years After Surgery
Women aged 50 or older who had less-frequent mammography 3 years after curative surgery for early-stage breast cancer had similar outcomes as women who had annual mammography, according to results from the Mammo-50 trial presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS03-02)....
Skipping Adjuvant Radiotherapy May Not Impact Risk of Recurrence or Progression in Patients With Low-Risk DCIS
Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable 5-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the 2023 San...
Potentially Targetable Fusion RNAs May Be More Common in Metastatic Breast Cancer Than Previously Realized
Comprehensive profiling of fusion RNAs present in a large cohort of metastatic breast tumors revealed unique fusion mutations that may be therapeutically targetable, according to results presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS03-09). Fusion mutations occur when a...
Recipients of 2023 Susan G. Komen Breast Cancer Awards Honored
Susan G. Komen presented its 2023 Breast Cancer Awards to four physician-scientists and one research advocate for their contributions to advancing breast cancer discoveries and improving patient outcomes. The five recipients were recognized at the Susan G. Komen Breast Cancer Awards event in San...
Genetic Characteristics of HER2-Low Advanced Breast Cancers May Guide Treatment Selection
Researchers have revealed significant differences in the genetic characteristics of HER2-low advanced breast cancers, which may lead to the development of novel therapeutics for patients, according to recent findings presented by Kahn et al at the 2023 San Antonio Breast Cancer Symposium (Abstract...
Using Estrogen Levels to Predict Who May Benefit From Preventive Treatment With Anastrozole
Investigators have found that estrogen levels measured through blood tests may be predictive of which individuals at high risk of breast cancer will benefit from aromatase inhibitors, according to a recent study presented by Cuzick et al at the 2023 San Antonio Breast Cancer Symposium (Abstract...
Amy Tiersten, MD, on Metastatic Breast Cancer: A Possible Chemotherapy-Free Front-Line Regimen
Amy Tiersten, MD, of the Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses findings from the ASPIRE trial, which showed the combination of anastrozole, palbociclib, trastuzumab, and pertuzumab in the front-line setting was well tolerated and effective, with a clinical...
Sara A. Hurvitz, MD, on Metastatic Breast Cancer: New Data on Tucatinib and Trastuzumab Emtansine
Sara A. Hurvitz, MD, of Fred Hutchinson Cancer Research Center, University of Washington, discusses phase III findings of the HER2CLIMB-02 study, which showed the combination of tucatinib and trastuzumab emtansine improved progression-free survival in patients with previously treated,...
Younger Postmenopausal Patients With Early-Stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy
Almost all postmenopausal patients aged 50 to 69 with stage I hormone receptor–positive breast cancer and low scores on a common genetic test who opted out of adjuvant radiotherapy were disease-free 5 years after surgery, according to results from the IDEA clinical trial presented at the 2023 San...
Patients With HR-Positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence
Using fertility preservation and/or assisted reproductive technologies (ART) did not adversely impact 3-year cancer recurrence rates among patients with hormone receptor–positive breast cancer who paused endocrine therapy to become pregnant, according to results from the POSITIVE trial presented at ...
Exercise May Boost Quality of Life for Patients With Metastatic Breast Cancer
Patients with metastatic breast cancer who took part in a 9-month structured exercise program reported less fatigue and an improved quality of life compared to those who did not participate in the exercise program, according to results from the PREFERABLE-EFFECT trial presented at the 2023 San...
Novel Targeted Therapies May Benefit Patients With Metastatic Hormone Receptor–Positive/HER2-Negative Breast Cancer
Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patients with metastatic hormone receptor–positive/HER2-negative breast cancer. The data were shared in oral...
Risk Model May Accurately Predict Aromatase Inhibitor Nonadherence
A novel risk model may be effective at using baseline sociodemographic and financial measures to predict the risk of long-term aromatase inhibitor nonadherence among patients with breast cancer, according to new findings presented by Hershman et al at the 2023 San Antonio Breast Cancer Symposium...
Novel Selective Biomarker Tool May Help Select Effective Targeted Therapies in Patients With Metastatic Breast Cancer
A novel selective biomarker tool (Troplex) may help select which antibody-drug conjugate therapy could be most effective in patients with metastatic breast cancer, according to findings presented by Robbins et al at the 2023 San Antonio Breast Cancer Symposium (Abstract PO3-13-11). Background...
Study Finds Link Between T-Cell Diversity in Peripheral Blood, Patient Age, and Stage of Breast Cancer Development
A large cohort study of peripheral blood T-cell receptor (TCR) clonotype diversity in patients with breast cancer diagnosed with either ductal carcinoma in situ or de novo stage IV disease has found that the diversity of T cells is associated with age and intratumor immune status and might be...
Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer
A combination of two HER2-targeted drugs—tucatinib and ado-trastuzumab emtansine (T-DM1), extended progression-free survival among patients with unresectable, locally advanced, or metastatic HER2-positive breast cancer compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial...
Neoadjuvant Chemotherapy May Help Some Patients With Breast Cancer Skip Regional Nodal Irradiation
For patients whose breast cancer converted from lymph node–positive to lymph node–negative disease after neoadjuvant chemotherapy, skipping adjuvant regional nodal irradiation did not increase the risk of disease recurrence or death 5 years after surgery, according to results from the NRG...
Regular Screening Mammograms May Significantly Reduce Breast Cancer Mortality, Swedish Study Shows
Patients who regularly attend screening mammograms may have a reduced risk of breast cancer mortality, according to recent findings presented by Smith et al at the Radiological Society of North America (RSNA) 2023 Scientific Assembly and Annual Meeting (Abstract R1-SSBR10-4). Background Early...
TROPION-Breast01 and DESTINY-Breast04: Antibody-Drug Conjugates of Benefit in Patients With Metastatic Breast Cancer
The TROP-2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) significantly improved progression-free survival over standard chemotherapy in the TROPION-Breast01 trial involving patients with previously treated, hormone receptor–positive, HER2-negative, unresectable and/or...
Incidence of Breast Cancer After False-Positive Mammography
In a Swedish study reported in JAMA Oncology, Mao et al found that women with a false-positive mammography result were more likely to be subsequently diagnosed with breast cancer compared to women with no false-positive result. Study Details The study involved data from 45,213 women who received a...
Urban Environmental Exposures and Incidence of Breast Cancer
Investigators have uncovered that North Carolina’s urban counties may have higher overall incidences of breast cancer than its rural counties, especially at early stages at diagnosis, according to a recent study published by Gearhart-Serna et al in Scientific Reports. These findings may serve as a...
From a Small Town in the Rust Belt, Dennis J. Slamon, MD, PhD, Plays a Big Role in Changing the Face of Breast Cancer Treatment
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Dennis J. Slamon, MD, PhD, one of the principals in the discovery and development of trastuzumab—the first monoclonal antibody used against an oncogene that altered our entire approach...
Axillary Soft-Tissue Involvement in Lymph Node–Positive Breast Cancer
In a single-institution retrospective analysis reported in the Journal of Clinical Oncology, Naoum et al found that pathologic exploration of axillary soft tissue in patients with lymph node–positive breast cancer is a critical element in predicting disease outcome and in determining axillary...
Hypofractionation Shows Comparable Results to Conventional Postmastectomy Radiation Therapy, With Added Benefits
In a major development in the treatment of breast cancer, short-course, or hypofractionated, radiation therapy has demonstrated comparable outcomes to conventional postmastectomy radiation therapy while reducing treatment breaks and financial toxicity, according to data presented at the 2023...
Early Breast Cancer: Effect of Radiotherapy to Regional Nodes
As reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), an individual patient meta-analysis has shown that more recent—but not older—trials of regional lymph node radiotherapy vs no radiotherapy in patients with early breast cancer showed benefits of...
Overall Survival With CTC Count–Driven Treatment in Advanced Breast Cancer
As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, and colleagues, the French phase III STIC CTC trial showed a nonsignificant overall survival benefit with a circulating tumor cell (CTC) count–driven approach to therapy vs physician’s choice in the first-line...
Partial-Breast Irradiation in Patients With Early-Stage Invasive Breast Cancer or DCIS
The American Society for Radiation Oncology (ASTRO) issued recommendations for patient-centered strategies for performing partial-breast irradiation in patients with early-stage invasive breast cancer or ductal carcinoma in situ (DCIS). The new clinical guidelines were published by Shaitelman et al ...
FDA Approves Capivasertib With Fulvestrant for Breast Cancer
On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations, as detected by an...
TROPION-Breast01 and DESTINY-Breast04: Antibody-Drug Conjugates of Benefit in Patients With Metastatic Breast Cancer
The TROP-2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) significantly improved progression-free survival over standard chemotherapy in the TROPION-Breast01 trial involving patients with previously treated, hormone receptor–positive, HER2-negative, unresectable and/or...
Vitamin D Supplements May Help Reduce Chemotherapy-Induced Peripheral Neuropathy
Investigators have found that patients with breast cancer who have insufficient levels of vitamin D prior to initiating treatment with paclitaxel may be more likely to experience peripheral neuropathy, according to a recent study published by Chen et al in JNCCN–Journal of the National...
Nadia Harbeck, MD, PhD, on High-Risk Early Breast Cancer: Overall Survival Data on Abemaciclib Plus Endocrine Therapy
Nadia Harbeck, MD, PhD, of Munich’s LMU University Hospital and the Ludwig Maximilian University, discusses an interim analysis of the monarchE trial on adjuvant abemaciclib plus endocrine therapy for patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer. The data...
Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Updated Results on Pembrolizumab Plus Chemotherapy
Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase III findings from the KEYNOTE-522 study, which showed neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to improve event-free survival compared with neoadjuvant chemotherapy alone in...
